A previous study has reported that GPF treatment upregulates the expression of miR-299-5p to downregulate activating transcription factor 2 (ATF2), thus leading to inhibited progression of NSCLC cells [33]. This evidence concerns the gene ATF2 and non-small cell lung carcinoma.